We are live on
!
Find out more
BI
BVF Inc Portfolio holdings
AUM
$3.14B
1-Year Est. Return
249.53%
This Fund
S&P 500
This Quarter
Est. Return
+14.28%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$3.14B
AUM Growth
+$168M
(+5.7%)
Cap. Flow
-$21.7M
Cap. Flow
% of AUM
-0.69%
Top 10 Holdings %
Top 10 Hldgs %
62.21%
Holding
45
New
4
Increased
10
Reduced
11
Closed
4
Top Buys
| 1 |
Alkermes
ALKS
|
+$62M |
| 2 |
Nektar Therapeutics
NKTR
|
+$56.9M |
| 3 |
Disc Medicine
IRON
|
+$43.2M |
| 4 |
Sutro Biopharma
STRO
|
+$22.6M |
| 5 |
AVR
Anteris Technologies
AVR
|
+$17.2M |
Top Sells
| 1 |
ABVX
Abivax
ABVX
|
+$68.5M |
| 2 |
MoonLake Immunotherapeutics
MLTX
|
+$62.1M |
| 3 |
Revolution Medicines
RVMD
|
+$50.5M |
| 4 |
RPTX
Repare Therapeutics
RPTX
|
+$26.9M |
| 5 |
4D Molecular Therapeutics
FDMT
|
+$15.2M |
Sector Composition
| 1 | Healthcare | 99.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Kymera Therapeutics
KYMR
$9.22B
| $458M | 14.6% |
5,502,710
| – | – |
|
|
2
MoonLake Immunotherapeutics
MLTX
$1.63B
| $298M | 9.5% |
16,001,284
-3,750,000
| -19% | -$62.1M |
|
|
3
Revolution Medicines
RVMD
$39.3B
| $278M | 8.85% |
2,856,782
-500,000
| -15% | -$50.5M |
|
|
4
Nektar Therapeutics
NKTR
$2.27B
| $184M | 5.87% |
2,559,595
+1,000,000
| +64% | +$56.9M |
|
5
Structure Therapeutics
GPCR
$3.6B
| $167M | 5.31% |
3,459,358
-19,664
| -0.6% | -$1.35M |
|
6
Mirum Pharmaceuticals
MIRM
$7.37B
| $146M | 4.66% |
1,584,727
+89,437
| +6% | +$8.41M |
|
7
GH Research
GHRS
$1.84B
| $122M | 3.87% |
8,650,158
-177,554
| -2% | -$2.73M |
|
|
PVLA
8
Palvella Therapeutics
PVLA
$2.15B
| $120M | 3.82% |
960,989
+81,980
| +9% | +$8.55M |
|
9
Zymeworks
ZYME
$1.81B
| $93.5M | 2.98% |
3,734,142
-204,499
| -5% | -$4.84M |
|
10
Xencor
XNCR
$1.11B
| $86M | 2.74% |
7,133,720
| – | – |
|
11
Stoke Therapeutics
STOK
$1.81B
| $82.9M | 2.64% |
2,547,557
+281,883
| +12% | +$9.24M |
|
12
Cullinan Oncology
CGEM
$1.09B
| $81.7M | 2.6% |
5,750,683
| – | – |
|
|
13
Disc Medicine
IRON
$2.87B
| $81.4M | 2.59% |
1,272,312
+622,312
| +96% | +$43.2M |
|
14
Xoma
XOMA
$710M
| $81.3M | 2.59% |
2,590,303
| – | – |
|
15
Olema Pharmaceuticals
OLMA
$1.04B
| $79M | 2.52% |
5,295,893
| – | – |
|
16
Tyra Biosciences
TYRA
$1.96B
| $75.7M | 2.41% |
1,976,196
-151,469
| -7% | -$4.9M |
|
17
Monte Rosa Therapeutics
GLUE
$1.98B
| $73.4M | 2.34% |
4,460,886
+625,000
| +16% | +$12M |
|
|
18
Alkermes
ALKS
$8.6B
| $70.7M | 2.25% |
+2,000,000
| New | +$62M |
|
19
Kura Oncology
KURA
$998M
| $68.7M | 2.19% |
8,445,769
-171,393
| -2% | -$1.47M |
|
20
AC Immune
ACIU
$245M
| $54.5M | 1.74% |
19,822,436
| – | – |
|
|
CBIO
21
Crescent Biopharma
CBIO
$422M
| $50.5M | 1.61% |
2,748,763
| – | – |
|
22
Annexon
ANNX
$909M
| $48.2M | 1.54% |
8,698,173
-429,907
| -5% | -$2.42M |
|
23
Compass Therapeutics
CMPX
$394M
| $41.1M | 1.31% |
7,764,842
| – | – |
|
24
Immunocore
IMCR
$1.7B
| $39M | 1.24% |
1,294,463
-194,512
| -13% | -$6.29M |
|
|
SEPN
25
Septerna Inc
SEPN
$1.56B
| $32.5M | 1.04% |
1,353,249
-367,533
| -21% | -$9.66M |
|
Similar funds
GKWIM
LT
BP
SC
AWE
EAM
HIMCH
SCM